|
1
|
Finckh A, Gilbert B, Hodkinson B, Bae SC,
Thomas R, Deane KD, Alpizar-Rodriguez D and Lauper K: Global
epidemiology of rheumatoid arthritis. Nat Rev Rheumatol.
18:591–602. 2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
van der Woude D and van der Helm-van Mil
AHM: Update on the epidemiology, risk factors, and disease outcomes
of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 32:174–187.
2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Yu KH, Chen HH, Cheng TT, Jan YJ, Weng MY,
Lin YJ, Chen HA, Cheng JT, Huang KY, Li KJ, et al: Consensus
recommendations on managing the selected comorbidities including
cardiovascular disease, osteoporosis, and interstitial lung disease
in rheumatoid arthritis. Medicine (Baltimore).
101(e28501)2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mitrović J, Hrkač S, Tečer J, Golob M,
Ljilja Posavec A, Kolar Mitrović H and Grgurević L: Pathogenesis of
extraarticular manifestations in rheumatoid arthritis-a
comprehensive review. Biomedicines. 11(1262)2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Moshayedi S, Tasorian B and
Almasi-Hashiani A: The prevalence of osteoporosis in rheumatoid
arthritis patient: A systematic review and meta-analysis. Sci Rep.
12(15844)2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Raterman HG, Bultink IE and Lems WF:
Osteoporosis in patients with rheumatoid arthritis: An update in
epidemiology, pathogenesis, and fracture prevention. Expert Opin
Pharmacother. 21:1725–1737. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Baker R, Narla R, Baker JF and Wysham KD:
Risk factors for osteoporosis and fractures in rheumatoid
arthritis. Best Pract Res Clin Rheumatol. 36(101773)2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Yu XH, Yang YQ, Cao RR, Cai MK, Zhang L,
Deng FY and Lei SF: Rheumatoid arthritis and osteoporosis: Shared
genetic effect, pleiotropy and causality. Hum Mol Genet.
30:1932–1940. 2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Wysham KD, Baker JF and Shoback DM:
Osteoporosis and fractures in rheumatoid arthritis. Curr Opin
Rheumatol. 33:270–276. 2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Johnson C, Crowther S, Stafford MJ,
Campbell DG, Toth R and MacKintosh C: Bioinformatic and
experimental survey of 14-3-3-binding sites. Biochem J. 427:69–78.
2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Gardino AK, Smerdon SJ and Yaffe MB:
Structural determinants of 14-3-3 binding specificities and
regulation of subcellular localization of 14-3-3-ligand complexes:
A comparison of the X-ray crystal structures of all human 14-3-3
isoforms. Semin Cancer Biol. 16:173–182. 2006.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zhang Y, Liang Y, Feng L and Cui L:
Diagnostic performance of 14-3-3η and anti-carbamylated protein
antibodies in rheumatoid arthritis in Han population of Northern
China. Clin Chim Acta. 502:102–110. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Adel Y and Sadeq Y: 14-3-3η protein is
associated with disease activity and osteoporosis in patients with
rheumatoid arthritis. Reumatologia. 60:384–391. 2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Huang J, Zeng T, Zhang X, Tian Y, Wu Y, Yu
J, Pei Z, Liu Y, Hu T and Tan L: Clinical diagnostic significance
of 14-3-3η protein, high-mobility group box-1, anti-cyclic
citrullinated peptide antibodies, anti-mutated citrullinated
vimentin antibodies and rheumatoid factor in rheumatoid arthritis.
Br J Biomed Sci. 77:19–23. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hussin DAAH, Shaat RM, Metwally SS and
Awad M: The significance of serum 14-3-3η level in rheumatoid
arthritis patients. Clin Rheumatol. 40:2193–2202. 2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Shovman O, Gilburd B, Watad A, Amital H,
Langevitz P, Bragazzi NL, Adawi M, Perez D, Bornstein G, Grossman
C, et al: The diagnostic value of 14-3-3η protein levels in
patients with rheumatoid arthritis. Best Pract Res Clin Rheumatol.
32:610–617. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Maksymowych WP, Naides SJ, Bykerk V,
Siminovitch KA, van Schaardenburg D, Boers M, Landewé R, van der
Heijde D, Tak PP, Genovese MC, et al: Serum 14-3-3η is a novel
marker that complements current serological measurements to enhance
detection of patients with rheumatoid arthritis. J Rheumatol.
41:2104–2113. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zeng T, Tan L, Wu Y and Yu J: 14-3-3η
protein in rheumatoid arthritis: Promising diagnostic marker and
independent risk factor for osteoporosis. Lab Med. 51:529–539.
2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Sun Y, Hong L and Gao C: The association
among 14-3-3η protein, inflammation, bone remodeling and
osteoporosis in patients with rheumatoid arthritis. Pak J Med Sci.
36:872–876. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Gong X, Xu SQ, Wu Y, Ma CC, Qi S, Liu W
and Xu JH: Elevated serum 14-3-3η protein may be helpful for
diagnosis of early rheumatoid arthritis associated with secondary
osteoporosis in Chinese population. Clin Rheumatol. 36:2581–2587.
2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Liberati A, Altman DG, Tetzlaff J, Mulrow
C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J
and Moher D: The PRISMA statement for reporting systematic reviews
and meta-analyses of studies that evaluate healthcare
interventions: Explanation and elaboration. BMJ.
339(b2700)2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wells G, Shea B, O'Connell D, Peterson J,
Welch V, Losos M and Tugwell P: The Newcastle-Ottawa Scale (NOS)
for assessing the quality of nonrandomised studies in
meta-analyses, 2000.
|
|
23
|
Luo D, Wan X, Liu J and Tong T: Optimally
estimating the sample mean from the sample size, median, mid-range,
and/or mid-quartile range. Stat Methods Med Res. 27:1785–1805.
2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wan X, Wang W, Liu J and Tong T:
Estimating the sample mean and standard deviation from the sample
size, median, range and/or interquartile range. BMC Med Res
Methodol. 14(135)2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Higgins JPT, Thomas J, Chandler J,
Cumpston M, Li T, Page MJ and Welch VA: Cochrane handbook for
systematic reviews of interventions (version 6.0). Cochrane
Handbook for Systematic Reviews of Interventions, London, 2019.
|
|
26
|
Maksymowych WP, Boire G, van Schaardenburg
D, Wichuk S, Turk S, Boers M, Siminovitch KA, Bykerk V, Keystone E,
Tak PP, et al: 14-3-3η autoantibodies: Diagnostic use in early
rheumatoid arthritis. J Rheumatol. 42:1587–1594. 2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Mohamed AH, Abdellatif S and El-Noshokaty
EH: Serum level of 14-3-3η (Eta) protein as a diagnostic marker for
rheumatoid arthritis and potential correlation with disease
activity. MOJ Orthop Rheumatol. 7(280)2018.
|
|
28
|
El-Sherif WT, Nigm DA, Abd-Elsamea MH and
Kassem AM: Evaluation of serum protein 14-3-3η (Eta) as a novel
biomarker for rheumatoid arthritis. Egypt J Immunol. 26:163–175.
2019.PubMed/NCBI
|
|
29
|
Guan SZ, Yang YQ, Bai X, Wang Y, Feng KQ,
Zhang HJ, Dong M, Yang HW and Li HQ: Serum 14-3-3η could improve
the diagnostic rate of rheumatoid arthritis and correlates to
disease activity. Ann Clin Lab Sci. 49:57–62. 2019.PubMed/NCBI
|
|
30
|
Qu CH, Hou Y, Bi YF, Han QR, Jiao CH and
Zou QF: Diagnostic values of serum IL-10 and IL-17 in rheumatoid
arthritis and their correlation with serum 14-3-3η protein. Eur Rev
Med Pharmacol Sci. 23:1899–1906. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Salman E, Çetiner S, Boral B, Kibar F,
Erken E, Ersözlü ED, Badak SÖ, Bilici Salman R, Sertdemir Y, Çetin
Duran A and Yaman A: Importance of 14-3-3eta, anti-CarP, and
anti-Sa in the diagnosis of seronegative rheumatoid arthritis. Turk
J Med Sci. 49:1498–1502. 2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Zeng T and Tan L: 14-3-3η protein: A
promising biomarker for rheumatoid arthritis. Biomark Med.
12:917–925. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kilani RT, Maksymowych WP, Aitken A, Boire
G, St-Pierre Y, Li Y and Ghahary A: Detection of high levels of 2
specific isoforms of 14-3-3 proteins in synovial fluid from
patients with joint inflammation. J Rheumatol. 34:1650–1657.
2007.PubMed/NCBI
|
|
34
|
Kadiri M, Charbonneau M, Lalanne C, Harper
K, Balg F, Marotta A and Dubois CM: 14-3-3η promotes invadosome
formation via the FOXO3-snail axis in rheumatoid arthritis
fibroblast-like synoviocytes. Int J Mol Sci. 23(123)2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Tu J, Chen X, Dai M, Pan A, Liu C, Zhou Y,
Xia X and Sun L: Serum levels of 14-3-3η are associated with
increased disease risk, activity and duration of rheumatoid
arthritis in Chinese patients. Exp Ther Med. 20:754–761.
2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Munier CC, Ottmann C and Perry MWD: 14-3-3
Modulation of the inflammatory response. Pharmacol Res.
163(105236)2021.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Kim H, Lee K, Kim JM, Kim MY, Kim JR, Lee
HW, Chung YW, Shin HI, Kim T, Park ES, et al: Selenoprotein W
ensures physiological bone remodeling by preventing hyperactivity
of osteoclasts. Nat Commun. 12(2258)2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Hammam N, Salah S, Kholef EF, Moussa EM
and Marotta A: 14-3-3η Protein in serum and synovial fluid
correlates with radiographic damage and progression in a
longitudinal evaluation of patients with established rheumatoid
arthritis. Mod Rheumatol. 30:664–670. 2020.PubMed/NCBI View Article : Google Scholar
|
